Copyright Reports & Markets. All rights reserved.

Global Targeted Drugs for NSCLC Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Target EGFR
      • 1.4.3 Target ALK
      • 1.4.4 Target HER2
      • 1.4.5 Target ROS1
      • 1.4.6 Target BRAF
      • 1.4.7 Target MEK
      • 1.4.8 Target VEGFR2
      • 1.4.9 Target VEGF
      • 1.4.10 Target MET
    • 1.5 Market by Application
      • 1.5.1 Global Targeted Drugs for NSCLC Market Share by Application (2014-2025)
      • 1.5.2 Squamous Cell Carcinoma of NSCLC
      • 1.5.3 Adenocarcinoma of NSCLC
      • 1.5.4 Large Cell Carcinoma of NSCLC
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Targeted Drugs for NSCLC Market Size
    • 2.2 Targeted Drugs for NSCLC Growth Trends by Regions
      • 2.2.1 Targeted Drugs for NSCLC Market Size by Regions (2014-2025)
      • 2.2.2 Targeted Drugs for NSCLC Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Targeted Drugs for NSCLC Market Size by by Players
      • 3.1.1 Global Targeted Drugs for NSCLC Revenue by by Players (2014-2019)
      • 3.1.2 Global Targeted Drugs for NSCLC Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Targeted Drugs for NSCLC Market Concentration Ratio (CR5 and HHI)
    • 3.2 Targeted Drugs for NSCLC Key Players Head office and Area Served
    • 3.3 Key Players Targeted Drugs for NSCLC Product/Solution/Service
    • 3.4 Date of Enter into Targeted Drugs for NSCLC Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Targeted Drugs for NSCLC Market Size by Type (2014-2019)
    • 4.2 Global Targeted Drugs for NSCLC Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Targeted Drugs for NSCLC Market Size (2014-2019)
    • 5.2 Targeted Drugs for NSCLC Key Players in United States
    • 5.3 United States Targeted Drugs for NSCLC Market Size by Type
    • 5.4 United States Targeted Drugs for NSCLC Market Size by Application

    6 Europe

    • 6.1 Europe Targeted Drugs for NSCLC Market Size (2014-2019)
    • 6.2 Targeted Drugs for NSCLC Key Players in Europe
    • 6.3 Europe Targeted Drugs for NSCLC Market Size by Type
    • 6.4 Europe Targeted Drugs for NSCLC Market Size by Application

    7 China

    • 7.1 China Targeted Drugs for NSCLC Market Size (2014-2019)
    • 7.2 Targeted Drugs for NSCLC Key Players in China
    • 7.3 China Targeted Drugs for NSCLC Market Size by Type
    • 7.4 China Targeted Drugs for NSCLC Market Size by Application

    8 Japan

    • 8.1 Japan Targeted Drugs for NSCLC Market Size (2014-2019)
    • 8.2 Targeted Drugs for NSCLC Key Players in Japan
    • 8.3 Japan Targeted Drugs for NSCLC Market Size by Type
    • 8.4 Japan Targeted Drugs for NSCLC Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Targeted Drugs for NSCLC Market Size (2014-2019)
    • 9.2 Targeted Drugs for NSCLC Key Players in Southeast Asia
    • 9.3 Southeast Asia Targeted Drugs for NSCLC Market Size by Type
    • 9.4 Southeast Asia Targeted Drugs for NSCLC Market Size by Application

    10 India

    • 10.1 India Targeted Drugs for NSCLC Market Size (2014-2019)
    • 10.2 Targeted Drugs for NSCLC Key Players in India
    • 10.3 India Targeted Drugs for NSCLC Market Size by Type
    • 10.4 India Targeted Drugs for NSCLC Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Targeted Drugs for NSCLC Market Size (2014-2019)
    • 11.2 Targeted Drugs for NSCLC Key Players in Central & South America
    • 11.3 Central & South America Targeted Drugs for NSCLC Market Size by Type
    • 11.4 Central & South America Targeted Drugs for NSCLC Market Size by Application

    12 International Players Profiles

    • 12.1 Allergan
      • 12.1.1 Allergan Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Targeted Drugs for NSCLC Introduction
      • 12.1.4 Allergan Revenue in Targeted Drugs for NSCLC Business (2014-2019)
      • 12.1.5 Allergan Recent Development
    • 12.2 Amgen
      • 12.2.1 Amgen Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Targeted Drugs for NSCLC Introduction
      • 12.2.4 Amgen Revenue in Targeted Drugs for NSCLC Business (2014-2019)
      • 12.2.5 Amgen Recent Development
    • 12.3 ARIAD Pharmaceuticals (Takeda)
      • 12.3.1 ARIAD Pharmaceuticals (Takeda) Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Targeted Drugs for NSCLC Introduction
      • 12.3.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2014-2019)
      • 12.3.5 ARIAD Pharmaceuticals (Takeda) Recent Development
    • 12.4 Beacon Pharma Limited
      • 12.4.1 Beacon Pharma Limited Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Targeted Drugs for NSCLC Introduction
      • 12.4.4 Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2014-2019)
      • 12.4.5 Beacon Pharma Limited Recent Development
    • 12.5 BeiGene
      • 12.5.1 BeiGene Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Targeted Drugs for NSCLC Introduction
      • 12.5.4 BeiGene Revenue in Targeted Drugs for NSCLC Business (2014-2019)
      • 12.5.5 BeiGene Recent Development
    • 12.6 Biocon
      • 12.6.1 Biocon Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Targeted Drugs for NSCLC Introduction
      • 12.6.4 Biocon Revenue in Targeted Drugs for NSCLC Business (2014-2019)
      • 12.6.5 Biocon Recent Development
    • 12.7 Boehringer-Ingelheim
      • 12.7.1 Boehringer-Ingelheim Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Targeted Drugs for NSCLC Introduction
      • 12.7.4 Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2014-2019)
      • 12.7.5 Boehringer-Ingelheim Recent Development
    • 12.8 Celgene Corporation
      • 12.8.1 Celgene Corporation Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Targeted Drugs for NSCLC Introduction
      • 12.8.4 Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2014-2019)
      • 12.8.5 Celgene Corporation Recent Development
    • 12.9 Drug International Limted
      • 12.9.1 Drug International Limted Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Targeted Drugs for NSCLC Introduction
      • 12.9.4 Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2014-2019)
      • 12.9.5 Drug International Limted Recent Development
    • 12.10 Fujifilm Kyowa Kirin Biologics
      • 12.10.1 Fujifilm Kyowa Kirin Biologics Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Targeted Drugs for NSCLC Introduction
      • 12.10.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2014-2019)
      • 12.10.5 Fujifilm Kyowa Kirin Biologics Recent Development
    • 12.11 Genvio Pharma Limited
    • 12.12 Hetero Drugs
    • 12.13 ImClone Systems ‎(Eli Lilly)
    • 12.14 Incepta Pharmaceuticals
    • 12.15 Mylan
    • 12.16 Novartis
    • 12.17 Pfizer
    • 12.18 Reliance Lifesciences
    • 12.19 Roche
    • 12.20 AstraZeneca
    • 12.21 Cipla
    • 12.22 Teva
    • 12.23 OSI Pharmaceuticals
    • 12.24 Glenmark Pharmaceuticals
    • 12.25 Natco Pharma

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Targeted Drugs for NSCLC market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Targeted Drugs for NSCLC status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drugs for NSCLC development in United States, Europe and China.

      The key players covered in this study
      Allergan
      Amgen
      ARIAD Pharmaceuticals (Takeda)
      Beacon Pharma Limited
      BeiGene
      Biocon
      Boehringer-Ingelheim
      Celgene Corporation
      Drug International Limted
      Fujifilm Kyowa Kirin Biologics
      Genvio Pharma Limited
      Hetero Drugs
      ImClone Systems ‎(Eli Lilly)
      Incepta Pharmaceuticals
      Mylan
      Novartis
      Pfizer
      Reliance Lifesciences
      Roche
      AstraZeneca
      Cipla
      Teva
      OSI Pharmaceuticals
      Glenmark Pharmaceuticals
      Natco Pharma

      Market segment by Type, the product can be split into
      Target EGFR
      Target ALK
      Target HER2
      Target ROS1
      Target BRAF
      Target MEK
      Target VEGFR2
      Target VEGF
      Target MET

      Market segment by Application, split into
      Squamous Cell Carcinoma of NSCLC
      Adenocarcinoma of NSCLC
      Large Cell Carcinoma of NSCLC

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Targeted Drugs for NSCLC status, future forecast, growth opportunity, key market and key players.
      To present the Targeted Drugs for NSCLC development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Targeted Drugs for NSCLC are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now